All In Biotech

NDA 205004 · Fresenius Kabi USA

Bortezomib

Bortezomib · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Sep 20, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Nov 6, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,027

156 Phase 3, 82 recruiting

FAERS reports

33,996

32,180 serious, 6,006 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 20, 2021 Supplement 3 · Efficacy LabelLetter
  • Nov 6, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • BORTEZOMIB · BORTEZOMIB 3.5MG/VIAL · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Bortezomib" as an intervention, any sponsor and status, largest first.

All 1,027 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • plasma cell myeloma5,249
  • off label use3,253
  • drug ineffective2,307
  • neuropathy peripheral1,904
  • thrombocytopenia1,807
  • death1,591
  • pneumonia1,575
  • neutropenia1,428
  • diarrhoea1,414
  • fatigue1,162
  • anaemia1,136
  • disease progression1,072

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200415
200525
200617
200737
200878
2009161
2010248
2011313
2012409
2013556
2014800
20151,311
20161,077
20171,232
20181,699
20192,521
20203,037
20213,110
20223,923
20233,918
20243,760
20253,243
20262,506

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bortezomib* (Bortezomib)

2024 spending

$3.1M

Beneficiaries

719

4,286 claims

Per beneficiary

$4,318

$261.26 per unit

View as table
YearSpending
2020$2,261,525
2021$3,209,334
2022$4,278,056
2023$3,999,340
2024$3,104,837

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,307 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.